Drug Trial Radar · NCT06617325
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
450
Planned (sponsor's estimate)
Start
Nov 21, 2024
Primary completion
May 31, 2028
Study completion May 31, 2028
Sponsor
- Lead sponsor
- UCB Biopharma SRLUCB
- Sponsor type
- Industry
- First posted
- Sep 27, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity.
Conditions
- Systemic Lupus Erythematosus
Interventions
DZPDrug
Study participants will receive dapirolizumab pegol (DZP) at prespecified time-points.
PlaceboOther
Study participants will receive placebo at prespecified time-points.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Achievement of British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004)-based Composite Lupus Assessment (BICLA) response at Week 48Time frame: Week 48
Locations
245 sites in 23 countries. Site status is shown where the registry gives one.
Sl0044 50058
Avondale, Arizona · Recruiting
Sl0044 50550
Chandler, Arizona · Recruiting
Sl0044 50713
Gilbert, Arizona · Recruiting
Sl0044 50662
Glendale, Arizona · Recruiting
Sl0044 50052
Phoenix, Arizona · Recruiting
Sl0044 50677
Scottsdale, Arizona · Recruiting
Sl0044 50670
Searcy, Arkansas · Recruiting
Sl0044 50737
Beverly Hills, California · Recruiting
Sl0044 50775
Beverly Hills, California · Recruiting
Sl0044 50257
La Jolla, California · Recruiting
Sl0044 50275
La Palma, California · Recruiting
Sl0044 50755
Los Alamitos, California · Recruiting
Sl0044 50258
Los Angeles, California · Recruiting
Sl0044 50725
Menifee, California · Recruiting
Sl0044 50340
Orange, California · Recruiting
Sl0044 50316
San Leandro, California · Recruiting
Sl0044 50719
Aurora, Colorado · Recruiting
Sl0044 50239
Brandon, Florida · Recruiting
Sl0044 50630
Clearwater, Florida · Recruiting
Sl0044 50751
Coral Gables, Florida · Recruiting
Sl0044 50362
Gainesville, Florida · Recruiting
Sl0044 50766
Hollywood, Florida · Recruiting
Sl0044 50763
Margate, Florida · Recruiting
Sl0044 50747
Miami, Florida · Recruiting
Sl0044 50735
Miami, Florida · Recruiting
Sl0044 50681
Miami, Florida · Recruiting
Sl0044 50324
Plantation, Florida · Recruiting
Sl0044 50698
Tampa, Florida · Recruiting
Sl0044 50585
Winter Park, Florida · Recruiting
Sl0044 50566
Gainesville, Georgia · Recruiting
Sl0044 50659
Marietta, Georgia · Recruiting
Sl0044 50699
Chicago, Illinois · Recruiting
Sl0044 50717
Willowbrook, Illinois · Recruiting
Sl0044 50748
New Albany, Indiana · Recruiting
Sl0044 50319
Iowa City, Iowa · Recruiting
Sl0044 50074
Kansas City, Kansas · Recruiting
Sl0044 50586
Louisville, Kentucky · Recruiting
Sl0044 50023
Baton Rouge, Louisiana · Recruiting
Sl0044 50285
Lake Charles, Louisiana · Recruiting
Sl0044 50660
New Orleans, Louisiana · Recruiting
Showing 40 of 245 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.